Two months ago police say Andrew Racca shot and killed Carolyn Mattingly at her Potomac home, then drove away and shot himself nearby.
Shortly before the murder-suicide, police said Mattingly’s husband and Racca’s boss, C. Richard Mattingly, had accused Racca of theft from the nonprofit where they both worked—the Cystic Fibrosis Foundation, which is headquartered in Bethesda.
Montgomery County police spokeswoman Rebecca Innocenti said Friday that detectives from the Financial Crimes Section continue to investigate the theft allegations.
Racca, of Chevy Chase, had worked for the nonprofit for 10 years and at the time of his death was director of network operations, according to his LinkedIn profile.
C. Richard Mattingly is the chief operating officer and executive vice president at the nonprofit. Police said at the time of the Sept. 30 incident they were unable to find other links between Carolyn Mattingly, 57, and Racca, 42.
Meanwhile, the foundation made headlines in November for its $3.3 billion sale of future royalty rights in a company that creates drugs to treat Cystic Fibrosis. The foundation had committed $150 million to a small biotechnology company about 15 years ago, which led to the development of Kalydeco, a cystic fibrosis drug that has successfully treated the underlying cause of the disease in a small percentage of patients. It was approved by the Food and Drug Administration in 2012 and is priced at an estimated $300,000 per year, according to The New York Times.
They royalty payout is believed to be the largest financial return ever for a charitable organization, according to The Times. Royalty Pharma, a New York-based drug royalty invest firm, bought the royalties. The payout is about 20 times the foundation’s budget last year and dwarfs the annual fundraising of the charity, which raises about $130 million per year, according to the paper.
